GSK says ask approval lung drug despite mixed data
London (Reuters) – GlaxoSmithKline reiterated his plan to ask authorization regulatory to commercialize his new medication pulmonary key Relovair to mid-2012, despite spreading on Friday another series of joint trials results. The new inhalable daily decision-making drug showed superiority to the current drug of two shots per day Advair – sobre also of GSK-in one of the trials the chronic lung disease, but not in the other. These mixed results replicated those from other studies obtained in an extensive development program. However, the greatest British laboratory remains confident in the product. Hopes that the convenient single daily dose of pill attracts patients and help to position better as a replacement for Advair, which has annual revenues of more than 8,000 million dollars and is the largest product in sales of GSK. The company said that Relovair being developed along with Theravance, seek approval against the disease pulmonary obstructive chronic (COPD) in United States and Europe to mid this year. Authorization as a treatment for asthma will also be asked in Europe at the same time. In United States, GSK will continue to discussing the use of the medicinal product with the regulators in patients with...
Read More